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Abstract
Background: Despite continual improvements in the management of acute coronary syndromes, adherence to
guideline-based medications remains suboptimal. We aim to improve adherence with guideline-based therapy
following acute coronary syndrome using an existing service that is provided by specifically trained pharmacists,
called a Home Medicines Review. We have made two minor adjustments to target the focus of the existing service
including an acute coronary syndrome specific referral letter and a training package for the pharmacists providing
the service.
Methods/Design: We will be conducting a randomized controlled trial to compare the directed home medicines
review service to usual care following acute coronary syndromes. All patients aged 18 to 80 years and with a
working diagnosis of acute coronary syndrome, who are admitted to two public, acute care hospitals, will be
screened for enrolment into the trial. Exclusion criteria will include: not being discharged home, documented
cognitive decline, non-Medicare eligibility, and presence of a terminal malignancy. Randomization concealment
and sequence generation will occur through a centrally-monitored computer program. Patients randomized to the
control group will receive usual post-discharge care. Patients randomized to receive the intervention will be offered
usual post-discharge care and a directed home medicines review at two months post-discharge. The study
endpoints will be six and twelve months post-discharge. The primary outcome will be the proportion of patients
who are adherent to a complete, guideline-based medication regimen. Secondary outcomes will include hospital
readmission rates, length of hospital stays, changes in quality of life, smoking cessation rates, cardiac rehabilitation
completion rates, and mortality.
Discussion: As the trial is closely based on an existing service, any improvements observed should be highly
translatable into regular practice. Possible limitations to the success of the trial intervention include general
practitioner approval of the intervention, general practitioner acceptance of pharmacists’ recommendations, and
pharmacists’ ability to make appropriate recommendations. A detailed monitoring process will detect any barriers
to the success of the trial. Given that poor medication persistence following acute coronary syndrome is a
worldwide problem, the findings of our study may have international implications for the care of this patient
group.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12611000452998
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Optimal medication management is critical to improving
outcomes following acute coronary syndrome (ACS), yet
prescribing practices and patient behaviors often fall
below recognized targets [1-3]. Research demonstrates
that the prescribing of guideline-based medications fol-
lowing ACS, including antithrombotics, beta-blockers,
angiotensin-converting enzyme inhibitors, and statins,
has improved over recent years [4] but is not yet ideal
[3]. When patients with ACS leave hospital and return
to the community, however, a more significant problem
becomes apparent due to the premature discontinuation
of guideline-based therapies by patients and/or clinicians
[1-3]. Furthermore, the majority of the morbidity and
mortality that occurs in the early post-discharge period
can be attributed to a failure to appropriately use these
existing medications [5-8]. For example, premature
medication discontinuation, when measured at one
month post-discharge in a myocardial infarction popula-
tion, decreased 12-month survival by 8% [2]. While,
understandably, much of the focus on improving patient
outcomes following ACS has centered on the acute
phase of care, it is crucial that more attention is paid to
the development of new, post-discharge strategies to
improve outcomes following hospital discharge.
Similar to other developed countries [2], poor medica-
tion persistence following ACS has been recognized as
an unresolved problem in Australia [3,9]. A recent Aus-
tralia-wide quality improvement study, called Discharge
Management of Acute Coronary Syndrome (DMACS)
utilized an education-based intervention to improve in-
hospital, guideline-based prescribing and this resulted in
a significant improvement in the proportion of patients
prescribed four guideline-based medications at dis-
charge, from 57% at baseline to 69% post-intervention
(P < 0.0001) [3]. A telephone follow-up of the post-
intervention group, however, revealed a 17% decline in
the proportion of patients taking all four guideline-
based medications at three months post-discharge. This
equated to a 66% loss of the improvement in prescribing
that was recorded at discharge, by just three months
post-discharge and suggested that the intervention was
effective at improving in-hospital prescribing, but there
was little effect on long-term medication use. The
authors noted in their discussion that further commu-
nity follow-up once the patients were settled in their
homes could improve the poor rates of post-discharge
medication persistence.
ACS post-discharge services
Cardiac rehabilitation has been continually shown to
improve multiple outcomes following ACS, including
mortality [10]. As such, the DMACS study also aimed
to improve referral rates and uptake of cardiac rehabili-
tation. While post-intervention referral rates significantly
increased from 67% to 73% (P = 0.001), attendance rates
remained unchanged at just 33% [3], which is in line
with the low worldwide attendance rates for cardiac
rehabilitation programs [11]. A Cochrane review has
highlighted the potential for structured interventions to
successfully increase cardiac rehabilitation uptake; how-
ever, interventions aimed at improving cardiac rehabili-
tation completion rates have generally proven less
successful [12]. Although the benefits of cardiac rehabi-
litation are well-established, attendance and completion
rates remain low, and evidence-based strategies to over-
come these problems and increase access to the service
are yet to be recognized.
Cardiac rehabilitation programs are designed to
increase adherence to both pharmacological and non-
pharmacological therapies [13]. However, there have
been few evaluations of the specific effect of these pro-
grams on medication adherence. One study of a rela-
tively high-intensity cardiac rehabilitation program was
able to demonstrate an improvement in medication
adherence at three months post-discharge [14], but
despite these initial improvements, the benefit was
short-lived, with both treatment and control groups
reporting the same level of medication adherence at six
months post-discharge. There is a clear need for a more
intensive multidisciplinary approach to the post-dis-
charge management of ACS, including interventions
specifically directed at improving medication manage-
ment. These interventions should be designed to both
complement and promote the existing cardiac rehabilita-
tion programs, as well as being accessible to the large
majority of patients who currently find reasons not to
attend cardiac rehabilitation.
The Home Medicines Review (HMR) program is an
existing community-based service that has the potential
to be tailored to meet the needs of patients recently dis-
charged from hospital following ACS. Although this
potential has not been fully realized in the past [15],
HMRs may be used to particularly target patients’ per-
sistence and adherence to guideline-based medications
following ACS. The HMR service currently involves
general practitioner (GP) referral of patients to an
HMR-accredited pharmacist, often through a commu-
nity pharmacist liaison [16]. The accredited pharmacist
will visit the patient in their home, discuss their medica-
tion taking habits, and provide education or adherence
interventions where required. Following the home visit
the accredited pharmacist writes a report for the GP
noting their observations and any clinical adjustments
that could be made to the patient’s medication regimen.
Based on this report, the GP is expected to complete an
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macist’s recommendations which they agree to imple-
ment and/or follow up. The service is currently available
in Australia, free of charge to Australian citizens under
funding arrangements through the public health system,
Medicare Australia. The GP, accredited pharmacist, and
community pharmacist involved with an HMR service
are paid by way of reimbursement from Medicare Aus-
tralia. One of the eligibility criteria for HMRs is recent
hospital discharge [16] and the HMR service has been
demonstrated to be feasible as a post-discharge service
for patients following ACS in the Australian healthcare
setting [17]. However, the effect of this service on clini-
cal outcomes following ACS is unknown.
Justification for this trial
Programs allowing pharmacists to provide formal medi-
cation review services exist across many countries.
Although there are some regional differences in the
structure of these programs, they are generally designed
to improve the quality use of medicines and minimize
the potential for medication-related harm. Previous stu-
dies assessing patient outcomes following post-discharge
medication review services have found conflicting
results. The HOMER trial questioned the value of the
service as the intervention group had an increased hos-
pitalization rate at six months post-discharge [18]. Simi-
larly, Barker et al. trialed a home-based, post-discharge
medication review service in patients with congestive
heart failure (CHF) and found that patients in the inter-
vention group had significantly longer CHF hospital
stays, incidence rate ratio = 2.34 (P < 0.001) [19]. There
were no statistical differences in the other two primary
outcomes of death and hospital readmission rates. Con-
versely, Stewart et al. were able to demonstrate both a
short- and long-term benefit by reducing hospital read-
missions and mortality, following a post-discharge ser-
vice targeted at a population that was suspected to be at
a high risk for readmission [20,21]. While the goal of
reducing healthcare costs through fewer and shorter
hospitalizations appears appropriate, this outcome may
not be a suitable measure for a service focusing specifi-
cally on medication management. A review by Benbassat
et al. questioned the validity of hospital readmissions as
a marker for quality care and highlighted that the length
of hospital stays, readmission rates, and death appear to
be mostly predicted by unmodifiable causes, such as
age, disease severity, and co-morbidity [22]. The authors
concluded by highlighting the importance of improving
other 7clinical outcome measures, such as adherence to
guideline-based therapy and improving patient’ss e l f -
management abilities.
Although the interventions trialed in their studies
included a significant focus on improving medication
adherence, neither Holland et al. nor Barker et al. mea-
sured changes in this outcome. As such, both authors
were left to speculate over this outcome and how it may
have affected hospital readmission rates. Conversely,
Stafford et al. conducted a prospective, non-randomized,
controlled cohort study of a pharmacist-led service
aimed at improving warfarin therapy post-discharge and,
while there were no significant changes in readmission
or death rates over the 90-day follow-up period, the
intervention was associated with a reduced rate of
adverse bleeding events from warfarin therapy, 5.3% vs.
14.7% (P = 0.03) and increased persistence with therapy,
95.4% vs. 83.6% (P = 0.004) [23]. The pharmacists
involved in this trial were HMR-accredited, but also
received additional education, specific to the needs of
patients taking warfarin [24]. This ability to focus the
HMR service on specific patient groups has been pro-
posed as an avenue for improvement of the HMR ser-
vice and this warrants further attention through future
research [15]. We have considered both of these aspects
in the modification of the service planned for this trial
and have outlined that the period following hospital dis-
charge is an appropriate time to target ACS patients
due to their risk for harm resulting from premature
medication discontinuation [2,3]. Furthermore, we have
developed a detailed education program to help pharma-
cists address ACS-specific issues and encourage patient
behavior change by using a motivational approach to
the HMR patient interview.
Objectives
In this study, we aim to investigate the effect of an
adaptation of the currently available HMR service on
guideline-based medication adherence and persistence
following ACS. The service will be directed towards the
needs of ACS patients by educating the accredited phar-
macists involved about ACS-specific patient issues and
through improving the continuum of care by providing
consistent information in a structured HMR referral let-
ter. As such, the trialed service will be termed a directed
Home Medicines Review (dHMR). This is the first trial
in a series of studies entitled ‘Medication Reviews
ReDirected (MedReDi)’ which refers to the plan for
future research in this area, following a similar theme of
minor adjustments to the currently existing HMR ser-
vice, so that patients with other specific illnesses can be
targeted through new dHMR services. The overall inten-
tion will be to help patients become more familiar and
competent with their medication management aspect of
therapy - more simply, helping patients become
‘MedReDi’.
For the purpose of this study, guideline-based ACS
medication therapy refers to the four medication classes
as supported by ACS guidelines [25-27]. These
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enzyme (ACE) inhibitors/angiotensin II receptor block-
ers (ARBs); antithrombotics (aspirin and/or clopidogrel/
prasugrel and/or warfarin); beta-blockers; and statins.
Methods/Design
Overview
We will conduct a randomized controlled trial compar-
ing the dHMR service delivered at two months post-dis-
charge to usual care following an ACS admission.
Changes in the pharmacist referral process and an ACS-
specific education package to be completed by the study
pharmacists make this program different to the standard
HMR service. The primary outcome will be the propor-
tion of patients who are adherent to a complete, guide-
line-based ACS medication regimen at six and twelve
months post-discharge. Patients will be enrolled in hos-
pital during an admission for ACS. Figure 1 provides an
overview of the trial protocol. The design of the inter-
vention and monitoring system has been based on a
conceptual framework for the standardized evaluation of
chronic disease management interventions, as developed
by Lemmens et al. [ 2 8 ] .F i g u r e2i sas u m m a r yo ft h i s
framework and Figure 3 is a comparison of how the
components of this trial compare against the Lemmens
et al. framework.
This representation of the ‘Evaluation model for dis-
ease-management programs’ has been adjusted slightly
from the originally produced model to better reflect the
points of the framework that we consider relevant to
the HMR service (shown in further detail in Figure 3). It
is important to recognize that this framework highlights
the importance of considering patient-related factors,
professional-related factors, and health-system factors in
both the design and evaluation of interventions targeted
toward improving the management of chronic diseases.
These considerations have been particularly important
throughout the development of this trial
Setting
Patient enrolment and dHMR referral will be from the
two major tertiary referral hospitals in Tasmania, Aus-
tralia. The Royal Hobart Hospital (RHH) is a 490-bed
hospital with an 8-bed coronary care unit (CCU), percu-
taneous coronary intervention (PCI), and coronary
artery bypass grafting (CABG) facilities, and accepts
patients from across the state for CABG referrals [29].
The Launceston General Hospital (LGH) is a 300-bed
hospital with a 4-bed coronary care unit and PCI facil-
ities [30]. Both hospitals run cardiac rehabilitation pro-
grams that are offered to all ACS patients. Patients
admitted to these centers generally receive verbal and
written education regarding lifestyle changes following
ACS from nurses, and medication counseling from
nurses or pharmacists, prior to discharge.
Inclusion/Exclusion criteria
All patients aged 18 to 80 years with a primary diagnosis
of ACS presenting at the RHH and LGH will be consid-
ered for enrolment into the trial. The wide age range
has been chosen to detect differences in the discharge
management of patients across different age groups and
to examine the suitability of the dHMR intervention
across different age groups. The former problem has
been previously recognized as an area for further inter-
ventional focus by Alexander et al. in the CRUSADE
trial [31] and the latter has been recognized as an area
requiring further investigation through a qualitative
review of the HMR service [15].
Patients will be excluded from trial enrolment if they:
are not returning to their home following hospital dis-
c h a r g e( a st h i si sar e q u i r e m e n to ft h ee x i s t i n gH M R
service); are non-Medicare eligible (for example, not a
permanent Australian resident); have been diagnosed
with a level of cognitive impairment such that the pro-
cess of informed consent may be obscured; or have
been diagnosed with a malignancy that is expected to be
terminal within 12 months.
Randomization
We will use a computer-generated random sequence to
provide the randomization coding. Patients will be ran-
domized to the control or intervention groups following
computerized recognition that the patient meets the
inclusion criteria and has consented to trial involvement.
The correct entry of this information into the central
trial database will then enable the enrolling researcher
to unlock the randomization status for that participant.
Controls
Following randomization to the control group, patients
will be offered the usual care processes involved with
post-discharge management of ACS in Australia.
Through the public health system, patients are able to
attend a cardiac rehabilitation program at their local
hospital as well as a cardiologist follow-up appointment,
usually occurring at one month following discharge. The
cardiac rehabilitation programs from the two different
hospitals may vary slightly in their level of physical
activity, but the material covered in their information
sessions is similar.
Intervention
Patients in the intervention group will receive a dHMR
at approximately two months following discharge as
well as usual care. The time of two months post-
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patients have demonstrated that the period between
one and three months post discharge is when patients
are most vulnerable for medication discontinuation
[2,3,32]. This suggests that a service addressing both
the educational and clinical management aspects of
therapy may be most beneficial when offered in this
time period.
Figure 1 Trial protocol overview. ACS: Acute Coronary Syndrome; dHMR: Directed Home Medicines Review; GP: General Practitioner; AP:
Accredited Pharmacist.
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Page 5 of 17Intervention Processes
Patient Focus Professional Focus
Health System Factors
Organisational Design Inter-professional Relationships 
and Coordination
Outcomes
Patients selected 
for disease
management 
intervention
Assessing knowledge and 
providing education
Mediating psychosocial 
inputs (what do their friends 
say and is this correct)
Improve/correct 
Knowledge-base
Offer opportunities to 
develop skills and expertise 
Improve patient’s belief in 
their own actions and ability 
to improve (self-efficacy)
Positive behaviour change
Improved attitudes toward 
provision of appropriate care 
(behavioural intention)
Professional behaviour/practice 
changes
Design factors that enable the 
intervention processes
Design factors that are barriers to 
the intervention processes 
Combined effect of organisational 
enablers and barriers on overall 
intervention process
Is inter-professional 
collaboration able to occur?
What is the quality of this 
collaboration?
What happens when this 
doesn’t occur?
Patient selection processes
eg. Presence of disease
Presence of risk factors
Suspected non-adherence
Clinical Functional
Health Care 
Expenditure
Consumer 
Satisfaction
Figure 2 Summary of the Lemmens et al. framework [28]. This representation of the ‘Evaluation model for disease-management programs’
has been adjusted slightly from the originally produced model to better reflect the points of the framework that we consider relevant to the
HMR service (shown in further detail through Figure 3). It is important to recognize that this framework highlights the importance of considering
patient-related factors, professional-related factors, and health-system factors in both the design and evaluation of interventions targeted toward
improving the management of chronic diseases. These considerations have been particularly important throughout the development of this trial.
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recommended reasons for referral, the HMR service is
currently available in Australia for all ACS patients
following hospital discharge [16]. The uptake of this ser-
vice, however, may be largely limited by the absence of
HMR referral systems in this transitional period.
Intervention Processes
Patient Focus – dHMR interview Professional Focus – dHMR report;  
agreed management plan;
pharmacist education
Health System Factors
Organisational Design Inter-professional Relationships and 
Coordination
Outcomes
Patients selected for intervention 
– dHMR
Assessing knowledge and 
providing education
Mediating psychosocial inputs 
(what do their friends say and is 
this correct)
Improve/correct Knowledge-base 
– through consistent referral 
letters and consistency with 
dHMR report
Offer opportunities to develop 
skills and expertise – to 
pharmacists only
Improve patient’s belief in their 
own actions and ability to 
improve (self-efficacy)
Positive behaviour change
Improved attitudes toward 
provision of appropriate care 
(behavioural intention)
Professional behaviour/practice 
changes
Intervention enablers – consistency in 
dHMR referral letter content;
      pre-existing funding for dHMR service
Intervention barriers – GP approval and 
forwarding of dHMR referral letters
Combined effect of organisational enablers 
and barriers on overall intervention process
Is inter-professional collaboration able 
to occur – through follow-up report 
and agreed management plan
What is the quality of this 
collaboration – by written report only 
OR by telephone discussion OR by 
meeting discussion
What happens when this doesn’t 
occur – i.e. the control group
Patient selection processes –
Admission for ACS
Clinical
eg. adherence, 
readmissions
Functional
eg. QOL
Health Care Expenditure – 
dHMR costs vs functional 
and clinical outcome savings
Consumer Satisfaction – 
previously established
Figure 3 How the proposed dHMR service addresses the specific components of the Lemmens et al. framework [ 2 8 ] .A C S :A c u t e
Coronary Syndrome; dHMR: Directed Home Medicines Review; GP: General Practitioner; QOL: Quality Of Life. The blue text highlights the areas
of the framework where we are investigating the effect of a dHMR with specific detail provided for clarification.
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lored to maximize the potential for benefit from this
service in the ACS population. We propose to add to
the existing HMR service in several ways, making the
proposed dHMR service more directed toward the ACS
population.
Typically, HMRs are ordered by a referral letter gener-
ated by the patient’s GP. Referral letters may vary signif-
icantly in their level of detail, potentially leaving the
pharmacist with little direction prior to the patient
interview. This concern was highlighted as a potential
downfall of the service in a qualitative review that was
conducted in 2008 [15]. To address this issue, the enrol-
ling researchers will use a specifically designed database
that allows baseline data collection to automatically
populate sections of the HMR referral. The referral let-
ter will still be sent to the GP for approval and addition
of any further information, such as medications that
have changed since discharge. GP approval is a require-
ment for payment under the existing public service
arrangements, and having the GP engaged with the
intervention early should increase their willingness to
participate. This new approach, however, relieves the
GP from having to complete most of the referral data
and allows for simple addition of only useful informa-
tion. The GP may also find the information on this
referral letter useful when they receive the letter, as pre-
vious research has demonstrated that standard discharge
letters following ACS admissions do not always contain
a sufficient level of information and sometimes take too
long to reach the GP [3].
In addition to the specific referral letter, the service
will be further directed by offering accredited pharma-
cists across Tasmania an online education and assess-
ment package. In order for a pharmacist to complete an
interventional dHMR according to the trial protocol,
they will be required to have a current accreditation sta-
tus and have successfully completed the education and
assessment package. Upon completion of the education
and assessment package, accredited pharmacists will
gain recognition of continuing professional development
and an AUD$50 reimbursement for their time.
Developing the education and assessment package
Within our trial, accredited pharmacists are appropri-
ately poised to deliver education to patients at the HMR
interview and to GPs through the HMR reports. Addres-
sing both the patient and their GP in this fashion has
been recognized as an important factor to increase the
chance of improving patient outcomes through chronic
disease management interventions [28,33,34]. Further
education and specialization of accredited pharmacists
in the area of ACS secondary prevention should increase
the chance of the current service utilizing these oppor-
tunities for follow-on education.
The accredited pharmacist education and assessment
package will consist of five online lectures, as well as
several separate resource documents for pharmacists to
r e f e rt oa ta n yp o i n tt h r o u g h o u tt h eH M Rs e r v i c e .T h e
five online lecture topics are: an introduction to the trial
and the evidence to practice gaps for ACS; background
information about the hospital management of ACS; the
importance of cardiac rehabilitation and lifestyle modifi-
cations; evidence-based ACS medication management;
and methods for improving adherence to therapy follow-
ing ACS. The separate resource documents include a
‘chest pain action plan’, information on the use of short-
acting nitrates, and links and referral to specific material
available from the National Heart Foundation, Australia.
The material will be assessed using case-based examples
with multiple-choice questions (pass mark of 75%). The
full details of the development of the education and
assessment package will be published at a later stage.
Outcomes
All outcomes will be measured using blinded assessment
processes at the two study endpoints of six and twelve
months post-discharge. Each outcome will be a compar-
ison between the control and intervention groups. A
proposed conceptual framework for the standardized
evaluation of chronic disease management interventions
has been considered in the selection of the trial out-
comes and further trial evaluation [28]. Using a frame-
work to guide outcome selection has not only helped to
ensure that we are measuring the important clinical out-
comes from the intervention, but also highlighted the
individual steps of the intervention that require moni-
toring. Monitoring these individual steps, such as phar-
macist detection of drug-related problems and GP
acceptance of pharmacist recommendations, is impor-
tant to measure the level of alignment between the the-
oretical plan and the practical application of the
intervention. Such detailed monitoring and outcome
reporting may also elucidate areas of practice worthy of
further focus in future research.
Primary outcome
The primary outcome will be the proportion of patients
who are adherent to a complete, guideline-based ACS
medication regimen at the trial endpoints. The accepted
definition of adherence for this trial will be a medication
possession ratio (MPR) of 80% to 120% for all guideline-
based medications, which is a commonly accepted cut-
off for this measure [35-39]. MPR will be determined by
dividing the total number of days of medication supplied
by the total specified time period. This value can be
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tage of the time that the patient had medication avail-
able to take, a commonly used surrogate measure of
adherence. During the baseline interview, we intend to
record all possible pharmacies that a patient may attend
in order to make the dispensing records complete. If,
however, there is a significant shortfall in the complete-
ness of dispensing records, we will use self-report of
medication adherence as an alternate measure. The
four-item Morisky adherence questionnaire will be used
for this purpose [40]. This is a well-validated instru-
ment, being used previously with good predictive valid-
ity in patients at risk of cardiovascular disease [40,41].
In the case where a patient has a clearly documented
contraindication to one of the four guideline-based
medication classes, their medication regimen may still
be considered ‘complete’ provided they are taking all
other guideline-based medications. For example, a
patient with asthma not taking a beta-blocker but still
taking aspirin, an ACE inhibitor, and a statin, will be
considered in the same group as those prescribed all
four medications. This primary outcome comprehen-
sively assesses the overall impact of the intervention on
both GP prescribing behaviors and patient medication-
taking behaviors. In order to separately measure the
recognized problem of persistence with guideline-based
medications, we will complete a secondary analysis of
the primary outcome in the group of patients who are
prescribed a complete, guideline-based medication regi-
men at the time of discharge from hospital.
Secondary outcomes
Secondary outcomes will include hospital readmission
rates, length of hospital stays, changes in quality of life,
cardiac rehabilitation completion rates, smoking cessations
rates, and mortality. Hospital readmissions and mortality
will be further categorized as ACS-related or due to other
causes. Quality of life will be measured at six weeks post-
discharge as a baseline, pre-dHMR measure and again at
both study endpoints. The Euroqol ‘EQ-5D 3 L’ [42] will
be used to measure general quality of life and the Seattle
Angina Questionnaire (SAQ) [43] will be used to measure
cardiac-specific quality of life. Both instruments have been
validated when administered individually [43-46] and in
combination [47] to assess quality of life in patients with
coronary heart disease. In addition to a self-report of
smoking status at baseline and the study endpoints, we
will be further categorizing each smoker’s dependence on
cigarette smoking using the Fagerstrom Test for Nicotine
Dependence (FTND) [48].
Process outcomes
In addition to reporting the important clinical outcomes
that may be affected by the intervention, it is also
recognized that there are many individual components
of such interventions that can be measured and may
highlight barriers or enablers to the overall success of
the intervention [28]. From the professional side of the
dHMR, it will be important to measure GP acceptance
of the intervention through approval of dHMR referrals,
pharmacists’ recognition of drug-related problems, the
clinical relevance of the drug-related problems identi-
fied, and GP acceptance of pharmacists’ recommenda-
tions. Figures 4 and 5 represent our plans to measure
the effect of these professional and organizational bar-
riers on trial implementation.
From the patient’s perspective it is important to con-
sider, firstly, how the dHMR process may influence psy-
chological variables that have been previously
recognized as relevant to adherence behavior, as well as
how strongly these variables correlate to the outcome of
adherence within this particular trial setting. The con-
cepts we have chosen to consider and the validated
instruments that will be used to evaluate each construct
are detailed in Figure 6.
The concepts of knowledge [55-57], illness percep-
tion [49,58], beliefs about medications [59,60], and
self-efficacy [50,61] have all been studied separately in
coronary heart disease populations. In developing the
conceptual framework for the evaluation of chronic
disease interventions, however, Lemmens et al. recog-
nized the important interrelations between these con-
cepts and how this can affect the ultimate outcome of
patient behavior change [28]. Risk perception [51] and
adherence-specific behaviors [52] are two lesser stu-
died concepts that may also affect or predict adherence
and, as such, have been added to our model of assess-
ment. As discussed, we consider it important to mea-
sure and report on the effect of the dHMR on these
individual concepts, as well as the validity of the indi-
vidual concepts as predictors for adherence within this
trial setting. Again, the latter has been investigated on
an individual basis for some concepts, but the different
trial setting and the inclusion of further variables may
result in alternate outcomes. The full details of the
predictors of adherence recognized in our ACS popula-
tion will be published elsewhere. The following is a
brief summary of the questionnaires selected for this
purpose: to assess medication knowledge we have
selected recall of individual medication purpose as
adapted from Hope et al. [53]; for illness perception
we have selected the eight quantitative items of the
Brief Illness Perception Questionnaire (Brief IPQ) [49];
for risk perception we have selected the Perceived
Heart Risk Questionnaire (PHRQ) [51]; for beliefs
about medications we have selected eight items from
the Beliefs About Medicines Questionnaire (BMQ) [54]
and developed two items to assess the impact of cost
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to take them regularly’ and ‘Medications are not good
value for money’ which will be assessed on the same
5-point Likert scale as the BMQ questions; for self-
efficacy we have selected seven items from the Cardiac
Self-Efficacy Scale [50]; for adherence-specific beha-
viors we have selected the Tool for Adherence Beha-
vior Screening (TABS) [52].
Intervention Processes
Patient Focus Professional 
Focus
Health System Factors
Organisational 
Design
Inter-
professional 
Relationships 
and 
Coordination
Outcomes
Professional Focus
Improve/correct knowledge-base 
Offer opportunities to develop skills and expertise 
– education and assessment package for 
pharmacists
Improved attitudes toward provision of 
appropriate care (behavioural intention) – % of 
GPs producing agreed management plans 
following dHMR report
Professional behaviour/practice changes – partly 
measured through patient’s dispensing records, 
but may be obscured by primary non-adherence
Patients 
selected 
Patient selection 
processes
Evaluation Processes for MedReDi
Figure 4 Evaluation of the professional-focused components of the intervention [28]. The blue text in this figure highlights where the
professional focused components of the intervention fit into the Lemmens et al. framework. dHMR: Directed Home Medicines Review.
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naire’s selection and the reasons for abbreviation of full
questionnaires, where relevant, will be discussed in a
future publication on the predictors of adherence. All of
these questionnaires have been validated in populations
of patients with coronary heart disease.
Health System Factors
Organisational Design Inter-professional 
Relationships and 
Coordination
Intervention Processes
Patient Focus Professional 
Focus
Health System Factors
Organisational 
Design
Inter-
professional 
Relationships 
and 
Coordination
Outcomes
organisational enablers – 
pharmacist comments on 
referral letter quality
organisational barriers - % GP 
acceptance of dHMR referral
Combined effect of 
organisational enablers and 
barriers on overall intervention 
process - % dHMRs that 
progress per protocol 
compared to those that do not
Is inter-professional 
collaboration able to occur? – 
% dHMRs that progress per 
protocol
What is the quality of this 
collaboration? – written/
verbal/face to face
What happens when this 
doesn’t occur? – control group
Evaluation Processes for MedReDi
Patients 
selected 
Patient selection 
processes
O
Figure 5 Evaluation of the health system’s impact on the implementation of the intervention [28]. The blue text in this figure highlights
how the local health-system structure may affect the implementation of the intervention described within this trial protocol. Again, the relevant
points raised by the Lemmens et al. framework have been considered. dHMR: Directed Home Medicines Review.
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Intervention Processes
Patient Focus Professional 
Focus
Health System Factors
Organisational 
Design
Inter-
professional 
Relationships 
and 
Coordination
Outcomes
Knowledge - Medication purpose recall
Illness perception - Brief IPQ
Risk perception - PHRQ
Beliefs about medicines - BMQ
Adherence behaviours - TABS
Self efficacy - Cardiac Self-Efficacy Scale
Medication adherence and persistence - MPR 
and Morisky analysed separately
Evaluation Processes for MedReDi
Patients 
selected 
Patient selection 
processes
Figure 6 Evaluation of the patient focused component of the intervention [28,40,49-54]. This figure highlights the comprehensive
evaluation that we have designed for the patient-focused component of the intervention. IPQ: Illness Perception Questionnaire; PHRQ: Perceived
Health Risk Questionnaire; BMQ: Beliefs About Medicines Questionnaire; TABS: Tool for Adherence Behavior Screening; MPR: Medication
Possession Ratio.
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note that for the purpose of testing for predictors of
adherence, we will be considering two separate models.
In the first model, adherence will be measured by the
MPR and in the second model, adherence will be mea-
sured by the Morisky Adherence Questionnaire [40].
Both measures have individual benefits and limitations
to their use, but have been extensively validated in car-
diac settings [35,40,41,62,63]. It was considered impor-
tant to include the second model using a questionnaire
to assess adherence in order to maintain consistency
w i t ht h er e l i a n c eo nq u e s t i o n n a i r e sa st h em e t h o do f
assessment for all concepts. The complete questionnaire
set chosen for this study can be viewed in Additional
file 1.
Sample size
We are aiming to detect a change in the primary out-
come of 15% between the control and intervention
groups. This predicted change is based on the results of
the DMACS study, whereby a 12% post-intervention
improvement was observed on the proportion of
patients taking the same four guideline-based medica-
tions at discharge [3]. To detect a change of 15%,
assuming a control group result of 45%, a power to
detect a difference of 80% with alpha = 0.05, we require
a minimum sample size of 186 patients per group. To
account for an approximate dropout rate of 20%, we
aim to enroll 465 patients in total.
Data collection
Baseline data collection will occur in hospital at the time
of enrolment, immediately post-discharge from hospital
and at six weeks post-discharge - when the participants
will be sent their first questionnaire set. The in-hospital
baseline data collection will include the recording of tra-
ditional coronary risk factors, as well as the ‘cholesterol’
version of the INTERHEART Modifiable Risk Score
(IHMRS) [64]. This will allow for baseline comparison
of risk between the two groups. Although not validated
to calculate risk in a population of patients following a
coronary event, the IHMRS requires the recording of
risk factors in a way which emphasizes their correlation
to their level of actual risk and this remains relevant,
regardless of the patient’s degree of heart disease. For
example, the IHMRS requires the recording of smoking
status into several cutoffs depending on the number of
cigarettes smoked per day, which correlates indepen-
dently to heart attack risk, as opposed to simply record-
ing cigarette smoking status in an arbitrary fashion,
which is of lesser value with regard to risk comparisons.
The final baseline data collection point of six weeks
post-discharge for questionnaire mail-out reflects our
intention to gauge each patient’s status on each of the
questionnaires in the time directly before the HMR and
not while in hospital, as factors, such as adherence
behavior, may be very high in hospital but may signifi-
cantly decline over time following discharge
[2,3,14,65,66]. Patients in the intervention group will be
asked to ensure that they complete their questionnaire
before their pharmacist visit and pharmacists will record
whether or not this has happened as reported by the
patient. Patients in the control group will be given a
reminder telephone call if their questionnaires have not
been returned by three weeks from the mail-out date.
Accredited pharmacists’ successful completion of the
education and assessment package will be required prior
to starting any trial dHMR. This will be recorded
through an online system, specifically designed to guide
each pharmacist through to completion of this package,
while also monitoring their usage levels of the education
website via separate log in codes. Although completion
of the package is encouraged by an AUD$50 honorar-
ium, program completion cannot be enforced beyond
this level and those patients receiving a dHMR by a
pharmacist who has not successfully finished the educa-
tion and assessment package prior to the dHMR inter-
view will be excluded from the secondary on-treatment
analysis, as discussed in the ‘statistical analysis’ section.
Following the dHMR interview, data collection starts
with the pharmacist’s dHMR report and the agreed,
patient-GP management plan. Collection of these docu-
ments will allow for assessment of pharmacists’ recogni-
tion of drug-related problems, the recommendations
made to improve these problems, and the GPs’ accep-
tance of these recommendations, as described in Figures
4 and 5. Telephone follow-up will be considered two
months after the interview if these reports and manage-
ment plans have not been received. Recent amendments
to the Medicare-funded HMR reimbursement process
have strongly increased the requirement that an agreed
management plan be formulated following all HMRs,
which should help facilitate this data collection point.
Six and twelve months post-discharge follow-up will
include requests to community pharmacies for patient
dispensing records, hospital register checks for readmis-
sions and length of stays, a death’sr e g i s t r yc h e c kf o r
mortality, and questionnaire mail-out with a three-week
phone call reminder.
Statistical analysis
All baseline variables will be compared between the
control and intervention groups using independent sam-
ples t-tests for continuous variables and chi-squared
analysis for categorical variables. All outcomes will be
reported as descriptive comparisons between the control
and intervention groups, with significance reported at
alpha = 0.05. Where primary outcomes reach statistical
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comparison will be tested by univariate comparison with
stepwise addition into a multivariate model for those
with univariate significance of P < 0.1. Changes in each
group’s questionnaire results between baseline and study
endpoints, as well as differences between intervention
and control group’s questionnaire results, will be
reported. Further correlational investigations between
questionnaire results and adherence will be reported
elsewhere. As there are several potential barriers that
may prevent a patient randomized to the intervention
group from receiving a dHMR according to the proto-
col, we will use both an intention-to-treat analysis as
well as an on-treatment sensitivity analysis.
Ethical approval
This trial has received ethical approval through the Tas-
manian Health and Medical Human Research and Ethics
Committee. Approval number: H11821. All participating
patients will provide informed consent.
Discussion
Recent evidence supports the current need for an inter-
vention directed at improving the prescription of, and
patients’ adherence to, guideline-based therapy in the
period following ACS hospital discharge [2,3]. This trial
aims to achieve this outcome using an intervention that
is based on only minor adjustments to a currently exist-
ing and funded service, such that any success derived
from this trial may be easily translated into regular prac-
tice. The potential for providing directly applicable ben-
efits to society by using this proposed method was
recognized in a recent editorial by Davidson and Mac-
donald [67]. Should our intervention lead to an
improvement in the primary outcome, the inherent sus-
tainability of the intervention in a real world environ-
ment is one of its major strengths.
As mentioned through this paper, the DMACS study
demonstrated significant improvements in prescribing at
discharge, but these improvements were almost comple-
tely lost at three months post-discharge [3]. Therefore it
could be proposed that, ideally, the intervention
described within this trial would occur in conjunction
with a similar quality improvement study. This would
ensure that both the in-hospital and post-discharge
aspects of management were addressed together, allow-
ing for an even greater opportunity to demonstrate sus-
tained improvements. As the specific benefits from a
dHMR service directed at ACS patients are unknown,
however, it is logical to trial this service first, before
considering its position in conjunction with other inter-
ventions. Australia’s National Prescribing Service offers
kits to allow ongoing drug use evaluations similar to
that of the DMACS study, therefore a trial combining
an in-hospital intervention and a post-discharge dHMR
m a yb ef e a s i b l ef o rf u t u r er e s earch, should the current
trial lead to success worthy of this follow-up.
Although based on an existing, Medicare-funded ser-
vice, the treatment protocol faces several potential bar-
riers to success. Largely, this includes interprofessional
barriers, such as GP approval of the dHMR referrals and
GP acceptance of pharmacists’ recommendations. The
former point will be aided by the enrolling researcher
contacting the GP once randomization has been
revealed. Although GP approval of dHMR referrals may
affect the uptake of the intervention in this trial, the use
of a consistent and informative referral letter and a tele-
phone conversation to support this letter, could prove
to be advantageous over the current systems for initiat-
ing standard HMR referrals, which may not always be
this well-structured. The other barrier of GPs not
accepting pharmacists’ recommendations has been
raised due to previous research showing that GPs only
action approximately 45% of pharmacist’s recommenda-
tions following HMRs [68,69]. The educational material
provided to accredited pharmacists completing this trial,
however, should help guide pharmacists to make recom-
mendations which will be relevant post-ACS and simple
to implement. Furthermore, as the education package
has been based on the latest evidence in ACS manage-
ment, even if GPs do not accept all of the pharmacists’
recommendations, they should still be gaining useful
information from the dHMR reports. This may lead to
improved ACS management, irrespective of the rate at
which GPs accept pharmacists’ individual
recommendations.
Having the pharmacists complete the online training
package may also be another barrier to the successful
implementation of the trial protocol. The education and
assessment package should take approximately three
hours to complete and will be rewarded with recogni-
tion of continuing professional development and an
AUD$50 honorarium. We hope that these incentives
and the easy-to-use format of the material will help
facilitate the completion of the package. Through careful
consideration of the potential barriers recognized above,
the dHMR processes that we have developed have trans-
formed these barriers into opportunities to improve the
implementation of the intervention.
We have designed a trial to test the effect of minor
changes to an existing, funded model of intervention to
target the needs of a high-risk population. The concep-
tually derived intervention, based on the Lemmens et al.
framework, accommodates funding and other health-
system-related barriers which are critical for successful
implementation. The intervention will be assessed by
observing changes in medication adherence which is an
outcome that appropriately matches the aim of the
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from the application of this intervention on a worldwide
scale, should the intervention demonstrate positive out-
comes in the trial population of Australian ACS
patients.
Trial status
The trial has not yet started recruiting. The expected
start time is early 2012.
Additional material
Additional file 1: MedReDi Patient Questionnaire Set [40,49,55-59].
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